Use Cases

A European nutraceutical manufacturer sought to enter Gulf markets with a premium joint health supplement formulated with curcumin, collagen, and boswellia - a novel combination requiring local regulatory justification in Saudi Arabia, UAE, and Qatar.

The client had no existing presence in MENA, lacked knowledge of local regulatory bodies (SFDA, MOHAP, QCHP), and needed a full go-to-market infrastructure built from scratch - including adapted labelling, local distribution agreements, and commercial training.

• Market assessment: competitive landscape, pricing benchmarks, channel mapping across Gulf markets
• Full regulatory dossier preparation for SFDA (KSA), MOHAP (UAE), and QCHP (Qatar)
• Arabic labelling adaptation and packaging compliance review
• Local distributor identification, due diligence, and contract support
• Scientific training program for medical representatives and pharmacists

• 4 regulatory approvals obtained within 7 months
• 30% cost savings vs. direct market entry through optimized sourcing and distribution model
• Successful commercial launch in KSA, UAE, and Qatar simultaneously
• Distribution agreement secured with a regional pharma group covering 400+ pharmacies

A European medical device manufacturer producing a complex dermal delivery system (transdermal patches) needed to transfer its manufacturing operations to a North African CMO to reduce production costs while maintaining full EU MDR compliance and CE marking validity.

The transfer involved critical sterile manufacturing steps, complex supplier qualification at the receiving site, and dual regulatory alignment between EU MDR and local North African authority requirements - all within a tight 14-month deadline to avoid supply disruption.

• Phase 1 - Feasibility & Risk Assessment: gap analysis between source and receiving site capabilities
• Phase 2 - Transfer Planning & Governance: milestone-based project plan, KPIs, and regulatory roadmap
• Phase 3 - Technical Execution: process validation batches, analytical method transfer, supplier re-qualification
• Phase 4 - Oversight & Coordination: real-time deviation management, authority submissions, knowledge transfer documentation

• Transfer completed on schedule with zero critical quality deviations
• 20% reduction in unit manufacturing cost achieved post-transfer
• CE marking validity maintained throughout - no regulatory gap during transition
• Full technology transfer documentation package delivered, enabling future site audits

A growing dermocosmetics company with a fragmented portfolio of 40+ SKUs was experiencing margin erosion, unclear brand positioning, and stagnating growth despite a strong R&D pipeline. Leadership needed an external strategic perspective to restore direction and accelerate performance.

The company was investing across too many segments simultaneously - mass-market, pharmacy, and premium e-commerce - without a clear competitive differentiation in any of them. Internal resources were spread thin, and pricing inconsistency was eroding brand equity.

• Strategic diagnosis: full audit of business model, portfolio, financials, and organizational structure
• Market & competitive analysis: segment sizing, positioning benchmarking, unmet need identification
• Portfolio rationalization: SKU-level profitability analysis and strategic categorization (grow / maintain / discontinue)
• 3-year growth strategy development with phased roadmap and investment priorities
• Leadership alignment workshops to embed the new strategic direction across functions

• 45% revenue increase within 18 months of roadmap implementation
• 3 unprofitable product lines discontinued, freeing R&D and commercial resources
• 2 new premium dermocosmetic lines launched with clear clinical positioning
• Gross margin improved by 12 points through pricing restructuring and channel focus

A mid-sized pharmaceutical distributor operating in North Africa and the Middle East sought to expand its OTC portfolio with high-quality European-manufactured products across pain management, digestive health, and vitamins & minerals categories.

The client lacked established contacts with European manufacturers, had limited experience in regulatory due diligence for import compliance, and needed to negotiate favorable supply agreements without the internal expertise to assess technical and quality standards.

• Portfolio gap analysis and product selection strategy aligned with market demand
• European manufacturer mapping across France, Germany, Italy, and Spain
• Technical and regulatory due diligence: GMP certificates, dossier availability, stability data review
• Commercial negotiation support: pricing, MOQ, exclusivity terms, and supply security clauses
• Import regulatory file preparation for local authority submissions

• 5 qualified European suppliers selected and contracted within 4 months
• 12 new OTC products added to the portfolio across 3 therapeutic areas
• 40% faster time-to-launch vs. previous sourcing attempts without external support
• Exclusive distribution rights secured for 2 flagship products in the MENA region

A nutraceutical manufacturer with a growing product pipeline was struggling with long development cycles, unclear go/no-go decision frameworks, and poor coordination between R&D, regulatory, and marketing functions - resulting in repeated delays and cost overruns.

The R&D department operated in silos, with no standardized stage-gate process. Project ownership was unclear, review milestones were informal, and regulatory constraints were addressed too late in development - causing costly rework and re-formulation cycles.

• R&D workflow audit: end-to-end mapping of current processes, bottleneck identification, and time analysis
• Stage-gate process design with clear deliverables, decision criteria, and accountability at each phase
• Cross-functional coordination framework integrating R&D, regulatory, procurement, and marketing from day one
• KPI dashboard implementation: cycle time, first-time-right rate, budget adherence per project
• Team capability assessment and targeted upskilling recommendations

• Average development cycle reduced from 18 to 12 months - a 35% improvement
• 8 core R&D processes redesigned and standardized across the team
• Cross-functional alignment reduced late-stage rework by 60%
• Team productivity increased by 40% as measured by projects completed per quarter

An innovative European skincare company developed a novel active ingredient-based line targeting anti-aging and skin-barrier repair indications. To expand into MENA, regulatory dossiers had to be prepared for 3 markets - Saudi Arabia, Morocco, and the UAE - each with distinct regulatory frameworks and documentation requirements.

The product line included novel peptide complexes and plant-derived actives requiring safety justification under each market's cosmetic ingredient regulations. The client's in-house team had no MENA regulatory experience, and tight commercial timelines left no room for submission errors or resubmissions.

• Regulatory gap analysis: comparative review of SFDA, ONSSA (Morocco), and MOHAP requirements vs. existing EU documentation
• Ingredient safety justification packages for novel actives, including toxicological reviews and usage data compilation
• Full dossier preparation per market: safety assessments, stability data, labelling compliance, and ingredient notifications
• Authority liaison and submission tracking for all 3 markets simultaneously
• Post-approval compliance monitoring and variation management framework

• 100% first-submission approval rate across all 3 markets - zero resubmissions required
• 6 product lines approved and market-ready within an average of 5 months per market
• Client's MENA regulatory playbook developed for future product launches
• Commercial launch executed on schedule, generating €1.2M in first-year MENA revenue